Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Pulse Biosciences, Inc.NASDAQ: PLSE
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$24.4M, compared with -$18.9M a year earlier. Trailing-twelve-month EBITDA was -$79.6M.
Context
- EBITDA amounted to 20488.6% of revenue in FY2025.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$71.68M (+0.0%) for the fiscal year ending Dec 2026, a step up from the -36.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$24.4M-29.2% QoQ
- Last fiscal yearDec 2025
- -$71.71M-36.8% YoY
- LTMJun 2026
- -$79.6M-19.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.2% | -15.0% | +14.1 pp |
| 1 year | -36.8% | +0.0% | +36.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (71.71M) USD
- Year-over-year change
- -36.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (71.71M) | -36.8% |
| FY2024 | 2024-12-31 | (52.41M) | -31.3% |
| FY2023 | 2023-12-31 | (39.9M) | +30.2% |
| FY2022 | 2022-12-31 | (57.15M) | +8.6% |
| FY2021 | 2021-12-31 | (62.51M) | — |
EBITDA vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.0% is the 4th highest of 11, against a peer median of -95.2%.
- EBITDA amounts to 6717.4% of revenue for PLSE, versus a peer median of 105.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | -$4.11M USD | +87.8% | — | 1.4% | |
| LTM Mar 2026 | -$4.22M USD | -227.5% | — | 1.9% | |
| LTM Jun 2026 | -$29.53M USD | +74.2% | — | 1550.9% | |
| LTM Mar 2026 | -$34.69M USD | -123.1% | — | 6.0% | |
| LTM Mar 2026 | -$63.5M USD | +7.9% | — | 57.6% | |
| LTM Jun 2026 | -$79.6M USD | -19.0% | — | 6717.4% | |
| LTM Jan 2026 | -$128M USD | -87.3% | — | 152.9% | |
| LTM Jun 2026 | -$134.39M USD | -53.9% | — | 246.2% | |
| LTM Mar 2026 | -$155.38M USD | -103.1% | — | 23.0% | |
| LTM Mar 2026 | -€202.4M EUR | -4407.9% | — | 542.7% | |
| LTM Jun 2026 | -$679.22M USD | -533.9% | — | 15185.0% | |
| Peer median (excluding PLSE) | — | -95.2% | — | 105.2% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 700K | 0 | 0 | 350K |
| Cost of Revenue | 1.97M | 11.94M | 1.21M | 0 | 1.61M |
| Gross Profit | (550K) | (11.24M) | (1.21M) | 0 | (1.26M) |
| Gross Margin | -38.8% | -1606.3% | — | — | -360.0% |
| Research & Development | 28.64M | 20.84M | 27.8M | 32.34M | 44.72M |
| Selling, General & Admin | 33.82M | 25.97M | 15.78M | 23.92M | 32.03M |
| Operating Expenses | 62.46M | 46.81M | 42.37M | 56.26M | 75.68M |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| EBITDA | (62.51M) | (57.15M) | (39.9M) | (52.41M) | (71.71M) |
| EBITDA Margin | -4408.6% | -8164.3% | — | — | -20488.6% |
| Operating Income | (63.01M) | (58.06M) | (43.57M) | (56.26M) | (76.94M) |
| Operating Margin | -4443.9% | -8293.9% | — | — | -21982.6% |
| Interest Income | 0 | 0 | 2.46M | 2.67M | 4.21M |
| Interest Expense | 646K | 448K | 1.1M | 0 | 0 |
| Other Income / Expenses | (646K) | (448K) | 1.36M | 2.67M | 4.16M |
| Income Before Tax | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Pre-Tax Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Net Margin | -4489.4% | -8357.9% | — | — | -20794.6% |
| EPS (Basic) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| EPS (Diluted) | (2.28) | (1.72) | (0.88) | (0.92) | (1.08) |
| Weighted Avg Shares | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
| Weighted Avg Shares (Diluted) | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.